Biological E seeks EUA for Corbevax for children in five-12 age group
Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine against COVID-19
Biological E has applied for Emergency Use Authorisation (EUA) for its COVID vaccine Corbevax for children in five-to-12 age bracket, official sources said yesterday.
In February, the company had received the EUA for Corbevax from the Drugs Controller General of India (DCGI) for the 12 to 18 age group.
Corbevax is India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine against COVID-19.
The RBD is a part of the spike protein of SARS-CoV-2. The virus uses the spike protein to attach itself to host cells.
The DCGI had also approved Corbevax for restricted use in emergency situation among adults on 28th December, 2021. Biological E received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results of the ongoing phase-II/III clinical study.
Edits by EP News Bureau